Suspension culture improves iPSC expansion and pluripotency phenotype
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Induced pluripotent stem cells (iPSCs) offer potential to revolutionize regenerative medicine as a renewable source for islets, dopaminergic neurons, retinal cells, and cardiomyocytes. However, translation of these regenerative cell therapies requires cost-efficient mass manufacturing of high-quality human iPSCs. This study presents an improved three-dimensional Vertical-Wheel® bioreactor (3D suspension) cell expansion protocol with comparison to a two-dimensional (2D planar) protocol. Methods: Sendai virus transfection of human peripheral blood mononuclear cells was used to establish mycoplasma and virus free iPSC lines without common genetic duplications or deletions. iPSCs were then expanded under 2D planar and 3D suspension culture conditions. We comparatively evaluated cell expansion capacity, genetic integrity, pluripotency phenotype, and in vitro and in vivo pluripotency potential of iPSCs. Results: Expansion of iPSCs using Vertical-Wheel® bioreactors achieved 93.8-fold (IQR 30.2) growth compared to 19.1 (IQR 4.0) in 2D (p < 0.0022), the largest expansion potential reported to date over 5 days. 0.5 L Vertical-Wheel® bioreactors achieved similar expansion and further reduced iPSC production cost. 3D suspension expanded cells had increased proliferation, measured as Ki67+expression using flow cytometry (3D: 69.4% [IQR 5.5%] vs. 2D: 57.4% [IQR 10.9%],p = 0.0022), and had a higher frequency of pluripotency marker (Oct4+Nanog+Sox2+) expression (3D: 94.3 [IQR 1.4] vs. 2D: 52.5% [IQR 5.6],p = 0.0079). q-PCR genetic analysis demonstrated a lack of duplications or deletions at the 8 most commonly mutated regions within iPSC lines after long-term passaging (> 25). 2D-cultured cells displayed a primed pluripotency phenotype, which transitioned to naïve after 3D-culture. Both 2D and 3D cells were capable of trilineage differentiation and following teratoma, 2D-expanded cells generated predominantly solid teratomas, while 3D-expanded cells produced more mature and predominantly cystic teratomas with lower Ki67+expression within teratomas (3D: 16.7% [IQR 3.2%] vs.. 2D: 45.3% [IQR 3.0%],p = 0.002) in keeping with a naïve phenotype. Conclusion: This study demonstrates nearly 100-fold iPSC expansion over 5-days using our 3D suspension culture protocol in Vertical-Wheel® bioreactors, the largest cell growth reported to date. 3D expanded cells showed enhanced in vitro and in vivo pluripotency phenotype that may support more efficient scale-up strategies and safer clinical implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“During expansion, a single iPSC expansion cycle in a 0.5 L VW® bioreactor vessel generated 997.1 (IQR: 850–1050) million human iPSCs with uniform 3D clusters of average 250 µm size (IQR: 125–324 µm), as previously reported by Cuesta-Gomez et al. from our group38.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [38]
In the citing paper
“For the current study, we used these patient-derived iPSC lines after quality control pluripotency characterization, viral clearance, normal karyotyping, mycoplasma absence, and pluripotent stem cell transcriptomics38.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [38]
In the citing paper
“We previously implemented PBS mini–Vertical Wheel® Bioreactors for ~100-fold iPSC expansion38 and achieved high efficiency in pancreatic progenitor cell differentiation (>90% PDX1 + NKX6.1 + )24.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [38]
In the citing paper
“Each cell line was scrutinized for routine pluripotent stem cell quality control criteria (ALP staining, phenotype, genetic analysis, and genomic integrity) as previously described and reported38.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575
Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells
Hogrebe, N. J., Augsornworawat, P., Maxwell, K. G., Velazco-Cruz, L., & Millman, J. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0430-6 · Cited by 373 · cited 1×
“After the discovery of human iPSCs in 2007 [22], initial iPSC expansion and differentiation experiments utilized two-dimensional (2D) planar expansion using feeder layers or supporting extracellular matrices, which resulted in approximately tenfold expansion [1, 2, 6, 17, 23, 24, 25].”
MethodKyttälä, A., Moraghebi, R., Valensisi, C., Kettunen, J., Andrus, C., Pasumarthy, K. K., Nakanishi, M., Nishimura, K., Ohtaka, M., Weltner, J., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.12.009 · Cited by 257
Herron, T. J., Rocha, A. M. D., Campbell, K. F., Ponce-Balbuena, D., Willis, B. C., Guerrero-Serna, G., Liu, Q., Klos, M., Musa, H., Zarzoso, M., et al. (2016) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.113.003638 · Cited by 257 · cited 3×
“Additionally, while cells grown in both conditions are capable of differentiating into tissues of interest [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], comparison of their pluripotency phenotype remains elusive.”
BackgroundGeneration of insulin-producing pancreatic β cells from multiple human stem cell lines
Hogrebe, N. J., Maxwell, K. G., Augsornworawat, P., & Millman, J. R. (2021) · Nature Protocols · doi:10.1038/s41596-021-00560-y · Cited by 211 · cited 4×
“Additionally, while cells grown in both conditions are capable of differentiating into tissues of interest [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], comparison of their pluripotency phenotype remains elusive.”
BackgroundMethodInfluentialMessmer, T., von Meyenn, F., Savino, A., Santos, F., Mohammed, H., Lun, A. T. L., Marioni, J. C., & Reik, W. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.099 · Cited by 156
Abecasis, B., Aguiar, T., Arnault, É., Costa, R., Gomes-Alves, P., Aspegren, A., Serra, M., & Alves, P. M. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.01.004 · Cited by 100 · cited 1×
“[71] 2017 ChiPS C4, ChiPS C12, ChiPS C15, ChiPS C18, ChiPS C22 Cellartis DEF‐CS Xeno‐Free 200 mL, Trapezoid‐paddle (DASGIP) 19‐fold/4 days”
Research works printed but not linked: 66
- Velazco-Cruz L, Goedegebuure MM, Maxwell KG, Augsornworawat P, Hogrebe NJ, Millman JR. SIX2 regulates human β Cell differentiation from stem cells and functional maturation in vitro. Cell Rep. 2020;31(8):107687. · DOI · Paper page
- Yabe SG, Fukuda S, Takeda F, Nashiro K, Shimoda M, Okochi H. Efficient generation of functional pancreatic β-cells from human induced pluripotent stem cells. J Diabetes. 2017;9(2):168–79. · DOI
- Funakoshi S, Miki K, Takaki T, Okubo C, Hatani T, Chonabayashi K, et al. Enhanced engraftment, proliferation and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes. Sci Rep. 2016;6(1):19111. · DOI · Paper page
- Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 2012;111(3):344–58. · DOI · Paper page
- Hatani T, Yoshida Y. TransplantationTransplantation of Human Induced Pluripotent Stem Cell-Derived CardiomyocytesHuman induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in a Mouse Myocardial InfarctionMyocardial infarction Model. In: Yoshida Y, editor. Pluripotent Stem-Cell Derived Cardiomyocytes. New York, NY: Springer US; 2021. p. 285–93. · doi:10.1007/978-1-0716-1484-6_24
- Gunhanlar N, Shpak G, van der Kroeg M, Gouty-Colomer LA, Munshi ST, Lendemeijer B, et al. A simplified protocol for differentiation of electrophysiologically mature neuronal networks from human induced pluripotent stem cells. Mol Psychiatry. 2018;23(5):1336–44. · DOI · Paper page
- Weed LS, Mills JA. Strategies for retinal cell generation from human pluripotent stem cells. Stem Cell Investig. 2017;4:65. · DOI
- Chichagova V, Hilgen G, Ghareeb A, Georgiou M, Carter M, Sernagor E, et al. Human iPSC differentiation to retinal organoids in response to IGF1 and BMP4 activation is line- and method-dependent. Stem Cells. 2020;38(2):195–201. · DOI · Paper page
- Millman JR, Pagliuca FW. Autologous pluripotent stem cell-derived β-like cells for diabetes cellular therapy. Diabetes. 2017;66(5):1111–20. · DOI
- Rivera-Ordaz A, Peli V, Manzini P, Barilani M, Lazzari L. Critical analysis of cGMP large-scale expansion process in bioreactors of human induced pluripotent stem cells in the framework of quality by design. BioDrugs. 2021;35(6):693–714. · DOI
- Nichols J, Smith A. Naive and primed pluripotent states. Cell Stem Cell. 2009;4(6):487–92. · DOI · Paper page
- Malik N, Rao MS. A review of the methods for human iPSC derivation. Methods Mol Biol. 2013;997:23–33. · DOI · Paper page
- Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell. 2008;3(6):595–605. · DOI · Paper page
- Lei Y, Schaffer DV. A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation. Proc Natl Acad Sci U S A. 2013;110(52):E5039–48. · DOI · Paper page
- Schulz TC, Young HY, Agulnick AD, Babin MJ, Baetge EE, Bang AG, et al. A Scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS ONE. 2012;7(5):e37004. · DOI · Paper page
- Borys BS, So T, Colter J, Dang T, Roberts EL, Revay T, et al. Optimized serial expansion of human induced pluripotent stem cells using low-density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors. Stem Cells Transl Med. 2020;9(9):1036–52. · DOI · Paper page
- Borys BS, Dang T, So T, Rohani L, Revay T, Walsh T, et al. Overcoming bioprocess bottlenecks in the large-scale expansion of high-quality hiPSC aggregates in vertical-wheel stirred suspension bioreactors. Stem Cell Res Ther. 2021;12(1):55. · DOI · Paper page
- Zweigerdt R, Olmer R, Singh H, Haverich A, Martin U. Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc. 2011;6(5):689–700. · DOI · Paper page
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72. · DOI · Paper page
- D’Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, et al. Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24(11):1392–401. · DOI · Paper page
- Johnson BV, Shindo N, Rathjen PD, Rathjen J, Keough RA. Understanding pluripotency—how embryonic stem cells keep their options open. Mol Hum Reprod. 2008;14(9):513–20. · DOI
- Kropp C, Kempf H, Halloin C, Robles-Diaz D, Franke A, Scheper T, et al. Impact of feeding strategies on the scalable expansion of human pluripotent stem cells in single-use stirred tank bioreactors. Stem Cells Transl Med. 2016;5(10):1289–301. · DOI
- Borys BS, So T, Colter J, Dang T, Roberts EL, Revay T, et al. Optimized serial expansion of human induced pluripotent stem cells using low-density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors. Stem Cells Transl Med. 2020;9(9):1036–52. · DOI · Paper page
- Dang T, Borys BS, Kanwar S, Colter J, Worden H, Blatchford A, et al. Computational fluid dynamic characterization of vertical-wheel bioreactors used for effective scale-up of human induced pluripotent stem cell aggregate culture. Canadian J Chem Eng. 2021;99(11):2536–53. · DOI · Paper page
- de Sousa PD, Bandeiras C, de Almeida FM, Rodrigues CAV, Jung S, Hashimura Y, et al. Scalable manufacturing of human mesenchymal stromal cells in the vertical-wheel bioreactor system: an experimental and economic approach. Biotechnol J. 2019;14(8):e1800716. · DOI
- Croughan MS, Giroux D, Fang D, Lee B. Novel single-use bioreactors for scale-up of anchorage-dependent cell manufacturing for cell therapies. In: Cabral JMS, Lobato de Silva C, Chase LG, Margarida Diogo M, editors. Stem cell manufacturing. Boston: Elsevier; 2016. p. 105–39. · DOI
- Rohani L, Borys BS, Razian G, Naghsh P, Liu S, Johnson AA, et al. Stirred suspension bioreactors maintain naïve pluripotency of human pluripotent stem cells. Commun Biol. 2020;3(1):492. · DOI
- Zhao T, Wang Z. GraphBio: a shiny web app to easily perform popular visualization analysis for omics data. Front Genet. 2022;13:957317. · DOI · Paper page
- Marfil-Garza BA, Pawlick RL, Szeto J, Kroger C, Tahiliani V, Hefler J, et al. Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) agonists in islet transplantation: Endogenous in vivo regulatory T cell expansion promotes prolonged allograft survival. American Journal of Transplantation. 2021;n/a(n/a). · DOI
- Szot GL, Koudria P, Bluestone JA. Transplantation of pancreatic islets into the kidney capsule of diabetic mice. JoVE. 2007;9:e404.
- Sułkowski M, Konieczny P, Chlebanowska P, Majka M. Introduction of exogenous HSV-TK suicide gene increases safety of keratinocyte-derived induced pluripotent stem cells by providing genetic “Emergency exit” switch. Int J Mol Sci. 2018;19(1):197. · DOI
- Baker D, Hirst AJ, Gokhale PJ, Juarez MA, Williams S, Wheeler M, et al. Detecting genetic mosaicism in cultures of human pluripotent stem cells. Stem Cell Rep. 2016;7(5):998–1012. · DOI
- Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29(12):1132–44. · DOI · Paper page
- Collier AJ, Panula SP, Schell JP, Chovanec P, Plaza Reyes A, Petropoulos S, et al. Comprehensive cell surface protein profiling identifies specific markers of human naive and primed pluripotent states. Cell Stem Cell. 2017;20(6):874-90.e7. · DOI · Paper page
- Nogueira DES, Rodrigues CAV, Carvalho MS, Miranda CC, Hashimura Y, Jung S, et al. Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel™ bioreactors. J Biol Eng. 2019;13(1):74. · DOI
- Rodrigues CA, Silva TP, Nogueira DE, Fernandes TG, Hashimura Y, Wesselschmidt R, et al. Scalable culture of human induced pluripotent cells on microcarriers under xeno-free conditions using single-use vertical-wheel™ bioreactors. J Chem Technol Biotechnol. 2018;93(12):3597–606. · DOI
- Manstein F, Ullmann K, Triebert W, Zweigerdt R. Process control and in silico modeling strategies for enabling high density culture of human pluripotent stem cells in stirred tank bioreactors. STAR Protoc. 2021;2(4):100988. · DOI
- Van Winkle AP, Gates ID, Kallos MS. Mass transfer limitations in embryoid bodies during human embryonic stem cell differentiation. Cells Tissues Organs. 2012;196(1):34–47. · DOI
- Horiguchi I, Urabe Y, Kimura K, Sakai Y. Effects of glucose, lactate and basic FGF as limiting factors on the expansion of human induced pluripotent stem cells. J Biosci Bioeng. 2018;125(1):111–5. · DOI
- Lotz S, Goderie S, Tokas N, Hirsch SE, Ahmad F, Corneo B, et al. Sustained levels of FGF2 maintain undifferentiated stem cell cultures with biweekly feeding. PLoS ONE. 2013;8(2):e56289. · DOI
- Onuma Y, Higuchi K, Aiki Y, Shu Y, Asada M, Asashima M, et al. A stable chimeric fibroblast growth factor (FGF) can successfully replace basic fgf in human pluripotent stem cell culture. PLoS ONE. 2015;10(4):e0118931. · DOI
- Mossahebi-Mohammadi M, Quan M, Zhang JS, Li X. FGF signaling pathway: a key regulator of stem cell pluripotency. Front Cell Dev Biol. 2020;8:79. · DOI · Paper page
- Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, et al. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. Stem Cells. 2009;27(8):1847–57. · DOI · Paper page
- Vernardis SI, Terzoudis K, Panoskaltsis N, Mantalaris A. Human embryonic and induced pluripotent stem cells maintain phenotype but alter their metabolism after exposure to ROCK inhibitor. Sci Rep. 2017;7:42138. · DOI · Paper page
- Takahashi S, Kobayashi S, Hiratani I. Epigenetic differences between naïve and primed pluripotent stem cells. Cell Mol Life Sci. 2018;75(7):1191–203. · DOI
- Díaz-Díaz C, Fernandez de Manuel L, Jimenez-Carretero D, Montoya MC, Clavería C, Torres M. Pluripotency surveillance by Myc-driven competitive elimination of differentiating cells. Dev Cell. 2017;42(6):585–99. · DOI
- Hu Z, Pu J, Jiang H, Zhong P, Qiu J, Li F, et al. Generation of naivetropic induced pluripotent stem cells from parkinson’s disease patients for high-efficiency genetic manipulation and disease modeling. Stem Cells Dev. 2015;24(21):2591–604. · DOI
- Ghosh A, Som A. Decoding molecular markers and transcriptional circuitry of naive and primed states of human pluripotency. Stem Cell Res. 2021;53:102334. · DOI
- Ficz G, Hore TA, Santos F, Lee HJ, Dean W, Arand J, et al. FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell. 2013;13(3):351–9. · DOI · Paper page
- Bratt-Leal AM, Carpenedo RL, McDevitt TC. Engineering the embryoid body microenvironment to direct embryonic stem cell differentiation. Biotechnol Prog. 2009;25(1):43–51. · DOI · Paper page
- Nickolls AR, Lee MM, Zukosky K, Mallon BS, Bönnemann CG. Human embryoid bodies as a 3D tissue model of the extracellular matrix and α-dystroglycanopathies. Dis Models Mech. 2020;13(6):042986. · DOI
- Lee ST, Yun JI, van der Vlies AJ, Kontos S, Jang M, Gong SP, et al. Long-term maintenance of mouse embryonic stem cell pluripotency by manipulating integrin signaling within 3D scaffolds without active Stat3. Biomaterials. 2012;33(35):8934–42. · DOI
- Ware CB, Nelson AM, Mecham B, Hesson J, Zhou W, Jonlin EC, et al. Derivation of naive human embryonic stem cells. Proc Natl Acad Sci U S A. 2014;111(12):4484–9. · DOI · Paper page
- Kiyokawa Y, Sato M, Noguchi H, Inada E, Iwase Y, Kubota N, et al. Drug-INDUCED Naïve iPS cells exhibit better performance than primed iPS cells with respect to the ability to differentiate into pancreatic β-cell lineage. J Clin Med. 2020;9(9):2838. · DOI
- Sougawa N, Miyagawa S, Fukushima S, Kawamura A, Yokoyama J, Ito E, et al. Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy. Sci Rep. 2018;8(1):3726. · DOI
- Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: tumor types and imaging characteristics. Radiographics. 2001;21(2):475–90. · DOI · Paper page
- Fu W, Wang SJ, Zhou GD, Liu W, Cao Y, Zhang WJ. Residual undifferentiated cells during differentiation of induced pluripotent stem cells in vitro and in vivo. Stem Cells Dev. 2012;21(4):521–9. · DOI
- Lee AS, Tang C, Cao F, Xie X, van der Bogt K, Hwang A, et al. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle. 2009;8(16):2608–12. · DOI · Paper page
- Bialecka M, Montilla-Rojo J, Roelen BAJ, Gillis AJ, Looijenga LHJ, Salvatori DCF. Humanised mice and immunodeficient mice (NSG) are equally sensitive for prediction of stem cell malignancy in the teratoma assay. Int J Mol Sci. 2022;23(9):4680. · DOI
- Elanzew A, Sommer A, Pusch-Klein A, Brüstle O, Haupt S. A reproducible and versatile system for the dynamic expansion of human pluripotent stem cells in suspension. Biotechnol J. 2015;10(10):1589–99. · DOI · Paper page
- Haraguchi Y, Matsuura K, Shimizu T, Yamato M, Okano T. Simple suspension culture system of human iPS cells maintaining their pluripotency for cardiac cell sheet engineering. J Tissue Eng Regen Med. 2015;9(12):1363–75. · DOI · Paper page
- Badenes SM, Fernandes TG, Cordeiro CS, Boucher S, Kuninger D, Vemuri MC, et al. Defined essential 8™ medium and vitronectin efficiently support scalable xeno-free expansion of human induced pluripotent stem cells in stirred microcarrier culture systems. PLoS ONE. 2016;11(3):e0151264. · DOI
- Meng G, Liu S, Poon A, Rancourt DE. Optimizing human induced pluripotent stem cell expansion in stirred-suspension culture. Stem Cells Dev. 2017;26(24):1804–17. · DOI
- Kwok CK, Ueda Y, Kadari A, Günther K, Ergün S, Heron A, et al. Scalable stirred suspension culture for the generation of billions of human induced pluripotent stem cells using single-use bioreactors. J Tissue Eng Regen Med. 2018;12(2):e1076–87. · DOI
- Nogueira DES, Rodrigues CAV, Carvalho MS, Miranda CC, Hashimura Y, Jung S, et al. Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel™ bioreactors. J Biol Eng. 2019;13:74. · DOI
- Manstein F, Ullmann K, Kropp C, Halloin C, Triebert W, Franke A, et al. High density bioprocessing of human pluripotent stem cells by metabolic control and in silico modeling. Stem Cells Transl Med. 2021;10(7):1063–80. · DOI · Paper page
Cited by
Dadheech, N., Bermúdez de León, M., Czarnecka, Z., Cuesta-Gomez, N., Jasra, I. T., Pawlick, R., Marfil-Garza, B., Sapkota, S., Verhoeff, K., Razavy, H., et al. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00409-y · Cited by 23
Self-citationVerhoeff, K., Cuesta-Gomez, N., Maghera, J., Dadheech, N., Pawlick, R., Smith, N., O’Gorman, D., Razavy, H., Marfil-Garza, B., Young, L. G., et al. (2025) · Transplantation · doi:10.1097/tp.0000000000005108 · Cited by 16
Self-citation
Metadata
- Authors
- Cuesta-Gomez, N., Verhoeff, K., Dadheech, N., Dang, T., Jasra, I. T., de Leon, M. B., Pawlick, R., Marfil-Garza, B., Anwar, P., Razavy, H., Zapata-Morin, P. A., Jickling, G., Thiesen, A., O’Gorman, D., Kallos, M. S., & Shapiro, A. M. J.
- Venue
- Stem Cell Research & Therapy
- Published
- 2023-06-06
- Volume
- 14
- Issue
- 1
- ISSN
- 1757-6512
- Cited by
- 48
- References
- 7
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Canada Research Chairs
- Juvenile Diabetes Research Foundation Canada
- Diabetes Canada
- Canadian Donation and Transplant Research Program
- Diabetes Research Institute Foundation of Canada
- Alberta Diabetes Institute
- Stem Cell Network
- Patronato del Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Fundacion para la Salud y la Educacion Dr. Salvador Zubirán
- CHRISTUS Excellence and Innovation Center
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suspension culture improves iPSC expansion and pluripotency phenotype. https://app.cochat.ai/papers/10.1186/s13287-023-03382-9
- The paper
- Cuesta-Gomez, N., Verhoeff, K., Dadheech, N., Dang, T., Jasra, I. T., de Leon, M. B., Pawlick, R., Marfil-Garza, B., Anwar, P., Razavy, H., Zapata-Morin, P. A., Jickling, G., Thiesen, A., O’Gorman, D., Kallos, M. S., & Shapiro, A. M. J. (2023). Suspension culture improves iPSC expansion and pluripotency phenotype. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-023-03382-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.